page-title

ADMdx Featured in PharmaVoice Celebrating Innovation April Issue

ADM Diagnostics, a global centralized imaging core lab for Central Nervous System clinical trials and diagnostic service provider, is featured in the April issue of PharmaVoice Celebrating Innovation. The magazine showcased breakthrough technologies and systems being implemented into drug discovery and development to improve clinical trial safety and efficacy.

PharmaVoice highlighted ADMdx’s core technologies that improve sponsors ability to enroll appropriate patient populations, prediction of clinical trajectory, detection and interpretation of drug effect and minimizing required number of subjects to power studies. “We are very pleased to be recognized by the PharmaVoice editorial staff for our innovative technology that is currently being applied in several clinical trials,” said Dawn Matthews, CEO of ADM Diagnostics. “Many of the companies and technologies featured in the publication will substantially improve the course of drug development in clinical trials and it is an honor to be part of that group.”

About ADM Diagnostics
ADM Diagnostics (ADMdx) is a centralized imaging core lab and diagnostic service provider that uses a proprietary analysis program combined with a team of Central Nervous Systems (CNS) experts to provide critical insights through advanced image analysis. Specializing in PET (FDG, amyloid, tau), MRI, fMRI, ASL and DTI, ADMdx allows can help pharmaceutical, biopharmaceutical, contract research organizations and academic core labs:
• Enroll the most appropriate patient selection
• Prediction of patient clinical trajectory
• Detection and interpretation of drug effect
• Minimized required number of subjects

For additional information on this topic or to receive a PDF of the presentation, please contact Craig Pennington (cpennington@admdx.com) at 314-299-4148.
To find more information on ADM Diagnostics please go to www.admdx.com.